132 related articles for article (PubMed ID: 37407689)
1. The role of TOP2A in immunotherapy and vasculogenic mimicry in non-small cell lung cancer and its potential mechanism.
Wu J; Zhang L; Li W; Wang L; Jia Q; Shi F; Li K; Liao L; Shi Y; Wu S
Sci Rep; 2023 Jul; 13(1):10906. PubMed ID: 37407689
[TBL] [Abstract][Full Text] [Related]
2. Vasculogenic mimicry-associated novel gene signature predicted prognosis and response to immunotherapy in lung adenocarcinoma.
Zhang L; Wu J; Yin WW; Hu J; Liao L; Ma J; Xu Z; Wu S
Pathol Res Pract; 2024 Jan; 253():155048. PubMed ID: 38147724
[TBL] [Abstract][Full Text] [Related]
3. [Expression of CD82/KAI1 and HIF-1α in non-small cell lung cancer and their relationship to vasculogenic mimicry].
Wu S; Cheng Z; Yu L; Song W; Tao Y
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):918-25. PubMed ID: 22152691
[TBL] [Abstract][Full Text] [Related]
4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
5. Cyclin-dependent kinase 5 controls vasculogenic mimicry formation in non-small cell lung cancer via the FAK-AKT signaling pathway.
Zhou X; Gu R; Han X; Wu G; Liu J
Biochem Biophys Res Commun; 2017 Oct; 492(3):447-452. PubMed ID: 28842255
[TBL] [Abstract][Full Text] [Related]
6. Expressions of KAI1 and E-cadherin in nonsmall cell lung cancer and their correlation with vasculogenic mimicry.
Ci H; Xu Z; Xu J; Wang Y; Wu S
Medicine (Baltimore); 2018 Oct; 97(40):e12293. PubMed ID: 30290593
[TBL] [Abstract][Full Text] [Related]
7. The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Li ZY; Zhang RG; Zhu F; Wu G
Int J Cancer; 2019 May; 144(9):2227-2238. PubMed ID: 30374974
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry.
Wu S; Yu L; Wang D; Zhou L; Cheng Z; Chai D; Ma L; Tao Y
BMC Cancer; 2012 Nov; 12():535. PubMed ID: 23170850
[TBL] [Abstract][Full Text] [Related]
9. Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry.
Wu S; Yu L; Cheng Z; Song W; Zhou L; Tao Y
J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):346-352. PubMed ID: 22684556
[TBL] [Abstract][Full Text] [Related]
10. Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
Zhao B; Wu M; Hu Z; Ma Y; Qi W; Zhang Y; Li Y; Yu M; Wang H; Mo W
Signal Transduct Target Ther; 2020 Jul; 5(1):117. PubMed ID: 32647187
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the correlation of vasculogenic mimicry, Notch4, DLL4, and KAI1/CD82 in the prediction of metastasis and prognosis in non-small cell lung cancer.
Wang Y; Yang R; Wang X; Ci H; Zhou L; Zhu B; Wu S; Wang D
Medicine (Baltimore); 2018 Dec; 97(52):e13817. PubMed ID: 30593175
[TBL] [Abstract][Full Text] [Related]
13. Relationship between the expression of ARHGAP25 and RhoA in non-small cell lung cancer and vasculogenic mimicry.
Shi F; Wu J; Jia Q; Li K; Li W; Shi Y; Wang Y; Wu S
BMC Pulm Med; 2022 Oct; 22(1):377. PubMed ID: 36207695
[TBL] [Abstract][Full Text] [Related]
14. MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer.
Li Y; Sun B; Zhao X; Wang X; Zhang D; Gu Q; Liu T
J Cell Mol Med; 2017 Dec; 21(12):3741-3751. PubMed ID: 28766880
[TBL] [Abstract][Full Text] [Related]
15. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
16. PP2A regulates metastasis and vasculogenic mimicry formation via PI3K/AKT/ZEB1 axis in non-small cell lung cancers.
Zhang Y; Wang X; Li A; Guan Y; Shen P; Ni Y; Han X
J Pharmacol Sci; 2022 Oct; 150(2):56-66. PubMed ID: 36055752
[TBL] [Abstract][Full Text] [Related]
17. Gallbladder cancer-associated fibroblasts promote vasculogenic mimicry formation and tumor growth in gallbladder cancer via upregulating the expression of NOX4, a poor prognosis factor, through IL-6-JAK-STAT3 signal pathway.
Pan MS; Wang H; Ansari KH; Li XP; Sun W; Fan YZ
J Exp Clin Cancer Res; 2020 Nov; 39(1):234. PubMed ID: 33153467
[TBL] [Abstract][Full Text] [Related]
18. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
19. Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype.
Yao L; Zhang D; Zhao X; Sun B; Liu Y; Gu Q; Zhang Y; Zhao X; Che N; Zheng Y; Liu F; Wang Y; Meng J
J Cell Mol Med; 2016 Sep; 20(9):1673-85. PubMed ID: 27240974
[TBL] [Abstract][Full Text] [Related]
20. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
